Role of fibroscan in assessing the extent of liver involvement among chronic hepatitis B and C cases




chronic liver diseases (CLD), hepatitis B viral infections, bloodborne, advanced fibrosis, Fibroscan, liver function tests (LFT), transient elastography


Chronic liver diseases (CLD) cause significant morbidity and mortality worldwide, accounting for approximately 2 million deaths annually. The majority of CLDs include alcoholic liver disease, chronic viral hepatitis, including hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), and hemochromatosis. Of these, hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for a substantial proportion of liver diseases which is responsible for liver damage ranging from minor disorders to liver cirrhosis and hepatocellular carcinoma (HCC). Fibroscan is a novel non-invasive method for assessing hepatic fibrosis by measuring liver stiffness.

The aim. The present study was conducted to know the prevalence of blood-born viral pathogens (HBV, HCV) among patients with chronic liver diseases (CLD) and also to assess the role of Fibroscan and liver function tests (LFT) in evaluating the extent of chronic liver disease.

Material and methods: The present study comprised 100 chronic liver disease patients attending the gastroenterology department. All the chronic liver disease cases were tested for Hepatitis B and Hepatitis C viral infections using a rapid Immunochromatography assay. Simultaneously they were subjected to liver function tests and fibroscan to assess the extent of fibrosis by staging from F0 to F4.

Results: When screened for bloodborne viral pathogens, 46 % were HBV positive, 10 % were HCV, and none were HIV positive. No co-infection was detected. HBV was identified as the most typical cause of CLD in about 46 %, followed by non-viral/non-infectious (alcoholic, metabolic, autoimmune) cause in 44 % and 10 %, the cause for CLD was HCV. As per fibroscan results, 80 % of HCV and 39 % of HBV patients were in the stage of cirrhosis/advanced fibrosis.

Conclusion: HBV was the predominant cause of CLD. Liver stiffness has recently been shown to be a good predictor of clinical outcomes. A fibroscan will help in the decision-making process in staging the disease and choice of treatment in viral hepatitis cases

Author Biographies

Pendyala Jyothi, Siddhartha Medical College

Assistant Professor

Department of Microbiology

Dasari Vanisree, Guntur Medical College

Associate Professor

Department of Microbiology

Durbha Satyanarayana Murty, Rangaraya Medical College

Associate Professor

Department of Microbiology

Kolli Prasanthi, Siddhartha Medical College

Associate Professor

Department of Microbiology


  1. Mukherjee, P. S., Vishnubhatla, S., Amarapurkar, D. N., Das, K., Sood, A., Chawla, Y. K. et. al. (2017). Etiology and mode of presentation of chronic liver diseases in India: A multi centric study. PLOS ONE, 12 (10), e0187033. doi:
  2. Asrani, S. K., Devarbhavi, H., Eaton, J., Kamath, P. S. (2019). Burden of liver diseases in the world. Journal of Hepatology, 70 (1), 151–171. doi:
  3. Sharma, A., Nagalli, S. (2021). Chronic Liver Disease. StatPearls. Treasure Island: StatPearls Publishing. Available at:
  4. World Health Organization Global hepatitis report 2017 (2017). World Health Organization, 83. Available at:
  5. Ayele, A. G., Gebre-Selassie, S. (2013). Prevalence and Risk Factors of Hepatitis B and Hepatitis C Virus Infections among Patients with Chronic Liver Diseases in Public Hospitals in Addis Ababa, Ethiopia. ISRN Tropical Medicine, 2013, 1–7. doi:
  6. Thanapirom, K., Suksawatamnuay, S., Tanpowpong, N., Chaopathomkul, B., Sriphoosanaphan, S., Thaimai, P., Srisoonthorn, N., Treeprasertsuk, S., Komolmit, P. (2022). Non-invasive tests for liver fibrosis assessment in patients with chronic liver diseases: a prospective study. Scientific Reports, 12 (1). doi:
  7. Castera, L., Forns, X., Alberti, A. (2008). Non-invasive evaluation of liver fibrosis using transient elastography. Journal of Hepatology, 48 (5), 835–847. doi:
  8. FibroScan® and Liver Disease. Available at:
  9. Satsangi, S., Chawla, Y. K. (2016). Viral hepatitis: Indian scenario. Medical Journal Armed Forces India, 72 (3), 204–210. doi:
  10. Cheemerla, S., Balakrishnan, M. (2021). Global Epidemiology of Chronic Liver Disease. Clinical Liver Disease, 17 (5), 365–370. doi:
  11. Foucher, J., Chanteloup, E., Vergniol, J., Castéra, L., Le Bail, B., Adhoute, X. et. al. (2006). Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut, 55 (3), 403–408. doi:
  12. Vilas, B. N., Lyra, P. R., Venkatesha, D. (2018). Coinfection of hepatitis B and hepatitis C virus among chronic liver disease patients in a tertiary care centre. Tropical Journal of Pathology and Microbiology, 4 (2), 128–133.
  13. Saravanan, S., Velu, V., Kumarasamy, N., Shankar, E. M., Nandakumar, S., Murugavel, K. G., Balakrishnan, P. et. al. (2008). The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India. International Journal of Infectious Diseases, 12 (5), 513–518. doi:
  14. Kundu, A., Mehta, S., Agrawal, B. K. et. al. (2015). Prevalence of Hepatitis B Virus and Hepatitis-C Virus among Chronic Liver Disease Patients in Northern Haryana Region of India. JK Science, 17 (4).
  15. Marcellin, P., Asselah, T., Boyer, N. (2002). Fibrosis and disease progression in hepatitis C. Hepatology, 36 (5B), s47–s56. doi:
  16. Malani, P. N. (2010). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. JAMA, 304 (18). doi:
  17. Fernández-Rodriguez, C. M., Gutiérrez, M. L., Serrano, P. L., Lledó, J. L., Santander, C., Fernández, T. P. et. al. (2004). Factors Influencing the Rate of Fibrosis Progression in Chronic Hepatitis C. Digestive Diseases and Sciences, 49 (11-12), 1971–1976. doi:
  18. Harrison, S. A. (2015). Utilization of FibroScan Testing in Hepatitis C Virus Management. Gastroenterol Hepatol (N Y), 11 (3), 187–189.
  19. van de Putte, D. F., Blom, R., van Soest, H., Mundt, M., Verveer, C., Arends, J. et. al. (2011). Impact of Fibroscan® on management of chronic viral hepatitis in clinical practice. Annals of Hepatology, 10 (4), 469–476. doi:
  20. The sustainable development goals and hepatitis B and C in the EU/EEA (2021). Available at:




How to Cite

Jyothi, P., Vanisree, D., Murty, D. S., & Prasanthi, K. (2022). Role of fibroscan in assessing the extent of liver involvement among chronic hepatitis B and C cases. ScienceRise: Medical Science, (5 (50), 47–51.



Medical Science